US President Joe Biden is planning to double the number of drugs which Medicare can negotiate prices for according to his budget proposal for the next year.
Fall of SVB has led to challenges for several biotechnology firms as they are exposed to the banks assistance in venture capital and initial public offerings.
Given the expertise available with service providers, bioavailability enhancement market is anticipated to grow at an annualized rate of 11% between 2022-2035.
Japan can anticipate a boom in the pharmaceutical generic imports in the coming years as the sector aims to bank on the forthcoming world-class trade fair.
Welsh life sciences landscape is showing incredible growth when it comes to revenue and employment within the sector, thereby helping the cause of the country.
